No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
CLDX241220P35000
- 0.00
- 0.000.00%
15min DelayClose Dec 20 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest35.00Strike Price0.00Turnover0.00%IV-39.22%PremiumDec 20, 2024Expiry Date9.86Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.65Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Express News | Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Celldex Therapeutics Doses First Patient in Study of Potential Inflammatory Disease Treatment
Express News | Celldex Therapeutics Inc - Subcutaneous Formulation to Be Added to Study in 2025
Express News | Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of Cdx-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock
Founder of Celldex Therapeutics Anthony Marucci Buys 40% More Shares